Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) — Spinogenix, Inc., a clinical-stage biopharmaceutical company developing…
Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance